Background: Pulmonary sclerosing hemangioma is a rare thoracic tumor, and pathophysiology or clinical course of this tumor is not yet fully described. Furthermore, there is no consensus on the standard operative procedure for this tumor. Material and Methods: Medical records of thirty-two patients, who underwent surgical resection of pulmonary sclerosing hemangioma from 1996 to 2007, were retrospectively reviewed. Results: Nineteen patients underwent lobectomy and thirteen patients underwent limited resection. Video-assisted thoracoscopic surgery was performed in 9 patients in the latter group. Lymph node dissection was done in 21 patients, and one patient was found to have lymph node metastasis of the tumor. There was no postoperative complication, no early death and no tumor-related late mortality. The mean follow-up duration was 39.3 months (2 months∼129 months), and all patients were free of local recurrence and distant metastasis during this period. There was no significant difference in patient's characteristics between the two groups, except that the mean hospital stay was shorter in limited resection group than in lobectomy group (p=0.0031). Conclusion: Pulmonary sclerosing hemangioma usually requires surgical resection for both diagnosis and treatment. Limited resection can decrease hospital stay with a surgical outcome comparable to lobectomy, and may be preferred to lobectomy if sufficient resection margin can be achieved.
INTRODUCTION
Pulmonary sclerosing hemangioma (PSH) is a rare benign tumor which was first described by Liebow and Hubbell [1] .
PSH usually presents as an asymptomatic solitary peripheral nodule, predominantly in women. PSH is generally considered as benign tumor, but some reports suggested the malignant potential of this tumor. The optimal surgical strategy for treating PSH has not been established. The purpose of this study is to compare the outcome of limited resection with that of lobectomy to determine the optimal surgical strategy of this tumor.
MATERIAL AND METHODS
Between January 1995 and December 2007, 32 patients underwent surgical resection of PSH at out institution. Their medical records were retrospectively reviewed to compare the 
RESULTS
The clinical characteristics and pathologic data of the study population are described in Table 2 There was no significant difference in basic patient's characteristics and surgical results between the two groups.
The mean hospital stay was significantly shorter in limited resection group (4.01 days) than in lobectomy group (6.5 days) (p=0.0031).
DISCUSSION
Pulmonary sclerosing hemangioma, first described by Liebow and Hubbell in 1956 [1] , is a rare primary pulmonary tumor. It predominantly involves women and is more common among Asians.
Although the biologic behavior of PSH is not clear and its histogenesis is still under debates, it has recently been claimed that PSH originates from primitive respiratory epithelial cells [2, 3] .
The clinical behavior of PSH has not been clearly elucidated. PSH presents mostly as a single solid mass in the lung, with right-side predominance, but it occasionally exhibits as multiple nodules [2] with an incidence of 4∼5%. It can also be found elsewhere (i.e. mediastinum or pleura) in the thorax [4] . We also experienced two cases of multiple 
CONCLUSION
Pulmonary sclerosing hemangioma usually requires surgical resection for both accurate diagnosis and adequate treatment.
Limited resection can decrease hospital stay and costs with a surgical outcome comparable to lobectomy. Recent progress in preoperative radiologic and pathologic diagnosis may reduce the probability of unnecessary lobectomy.
